#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glomerulonephritis Breast angiosarcoma Isodicentric chromosome 15 syndrome Hypoxic-ischaemic encephalopathy Anti-HLA antibody test positive Metastatic gastric cancer Non-Hodgkin's lymphoma Small cell lung cancer recurrent Oropharyngeal squamous cell carcinoma Cardiac arrest Thromboangiitis obliterans Small intestine neuroendocrine tumour Uterine leiomyosarcoma Optic ischaemic neuropathy Nephropathy More trials…

    Learn about Rare Diseases

    Hepatoblastoma – Diagnostics Angelman’s syndrome – Treatment Richter’s syndrome – Basic Information Antithrombin III deficiency – Life with Disease Castleman’s disease Loeys-Dietz syndrome – Treatment Propionic acidaemia – Life with Disease Primary mediastinal large B-cell lymphoma Systemic sclerosis pulmonary – Treatment Hepatic angiosarcoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Eltrombopag Potassium Chloride LIPASE Fedratinib Vinflunine Arachis Hypogaea (762) Golcadomide Interferon Gamma Glepaglutide JNJ-75276617 Lebrikizumab Etuvetidigene Autotemcel Dipyridamole ANUMIGILIMAB Lithium CEFTAROLINE FOSAMIL ATIRMOCICLIB Befiradol (18F) Fostemsavir Trometamol Flortaucipir (18F) More therapies…

    Learn about Your Condition

    Enteritis Primary hyperthyroidism Infantile apnoea Pustular psoriasis Embolism Depression Thyroid mass Vascular dementia Subdural haematoma Vertigo Plasma cell myeloma refractory Ear discomfort Marginal zone lymphoma Cartilage injury Uterine leiomyosarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Parc Tauli Hospital Universitari

Parc Tauli Hospital Universitari

Parc Del Tauli 1, Sabadell, 08208, Spain

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Safety and Effectiveness of Aticaprant with Antidepressants for Adults and Elderly with Major Depressive Disorder

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Major depression
    Investigated Drugs:
    • Aticaprant
    Belgium Bulgaria Czechia France Hungary Italy +5

  • A Study of Cabazitaxel and Pelvic Radiation Therapy Combined with Hormone Treatment for Patients with High-Risk Localized Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Cabazitaxel
    Belgium France Spain

  • Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Barzolvolimab
    • Epinephrine
    Belgium Bulgaria Czechia Denmark France Germany +5

  • Study of Lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

    Not recruiting

    3 1
    Investigated Drugs:
    • Lutikizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Study on Bepirovirsen for Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue Treatment

    Not recruiting

    3 1
    Investigated Diseases:
    • Chronic hepatitis B
    Investigated Drugs:
    • Bepirovirsen
    Bulgaria France Germany Greece Hungary Italy +3

  • Study Comparing 177Lu-PSMA-617 with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Abiraterone
    • Apalutamide
    • Bicalutamide
    Austria Belgium Czechia Denmark France Germany +4

  • Study of Nivolumab and Ipilimumab for Patients with Advanced Kidney Cancer and Intermediate or Poor Risk Factors

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    Austria Czechia France Greece Italy Poland +2

  • Study Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Ceralasertib
    • Docetaxel
    • Durvalumab
    Belgium France Germany Hungary Ireland Italy +4

  • Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Lung neoplasm malignant
    Investigated Drugs:
    • Domvanalimab
    • Durvalumab
    • Infliximab
    Belgium France Germany Greece Hungary Italy +4

  • Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Atezolizumab
    Belgium Czechia France Germany Greece Ireland +3
Previous Page
1 … 16 17 18 19 20 … 29
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!